Innate Pharma Reports Third Quarter 2026 Business and Financial Update
Innate Pharma S.A. released its financial results for the nine months ended September 30, 2026, highlighting a strengthened cash position and progress in its clinical pipeline.
Stocks · News reference
Earnings Scheduled For September 17, 2026
Companies Reporting Before The Bell • 111 (NASDAQ:YI) is projected to report earnings for its second quarter. • Innate Pharma (NASDAQ:IPHA) is projected to report quarterly loss at $0.16 per share on revenue of $9.10
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Innate Pharma Announces Updated Timing for PACIFIC-9 Phase 3 Trial Data Readout
Innate Pharma reported that AstraZeneca has adjusted the expected timeline for the high-level data readout of the Phase 3 PACIFIC-9 clinical trial to the first half of 2027.
8-K filing — UPEXI, INC. (UPXI)
Filed: 2026-10-13 AccNo: 0001477932-26-006194 Size: 4 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Upexi to Participate in Upcoming October Investor Conferences
Upexi, Inc. (NASDAQ: UPXI), a Solana-focused digital asset treasury company, announced that Chief Strategy Officer Brian Rudick will participate in three major investor conferences in October 2026: Maxim Growth Summit, Webull Emerging & Innovative Companies Webinar, and LD Micro 20th Annual Main Event. The company currently holds over 2.34 million SOL and reported digital asset revenue of $17.4 million for fiscal year 2026.
111, Inc. Sets Up Special Committee Of Three Independent Directors To Consider September 16 Proposal, Other Strategic Alternatives, Cautions No Decisions Made
Cantor Fitzgerald Reiterates Overweight on Upexi, Maintains $2 Price Target
Cantor Fitzgerald analyst Gareth Gacetta reiterates Upexi (NASDAQ:UPXI) with a Overweight and maintains $2 price target.